Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study

Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J., Schlingemann R. O., Axer-Siegel R., ...More

OPHTHALMOLOGY, vol.118, no.5, pp.831-839, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 118 Issue: 5
  • Publication Date: 2011
  • Doi Number: 10.1016/j.ophtha.2010.09.004
  • Journal Name: OPHTHALMOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.831-839
  • Hacettepe University Affiliated: Yes


Objective: To demonstrate noninferiority of a quarterly treatment regimen to a monthly regimen of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).